Celsion CEO Issues Letter to Stockholders
03 mars 2020 08h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., March 03, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announces that Michael H. Tardugno, the company’s chairman,...
Celsion Corporation Prices $4.8 Million Registered Direct Offering
28 févr. 2020 08h45 HE
|
Celsion CORP
LAWRENCEVILLE, NJ, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into securities purchase agreements with...
Celsion Corporation Announces DSMB has Confirmed Initial Safety of Weekly GEN-1 Dosing at 100 mg/m² in 15 Randomized Patients with Advanced Ovarian Cancer
06 févr. 2020 09h25 HE
|
Celsion CORP
Phase 2 Portion Will Continue After Patients Have Completed Their Full Treatment Regimen of up to 17 doses of GEN-1 plus Standard Chemotherapy LAWRENCEVILLE, N.J., Feb. 06, 2020 (GLOBE...
Principal Investigator Professor Riccardo Lencioni Presents Celsion ThermoDox® Trial Data at SPECTRUM 2020 Interventional Oncology Conference
04 févr. 2020 08h30 HE
|
Celsion CORP
Company reaffirms its projection for second pre-planned interim efficacy analysis for Phase III OPTIMA Study in the second quarter of 2020 LAWRENCEVILLE, N.J., Feb. 04, 2020 (GLOBE NEWSWIRE) --...
Celsion’s New Subsidiary in China to Serve as Beachhead for Commercializing ThermoDox® in China and Southeast Asia
18 déc. 2019 08h00 HE
|
Celsion CORP
Memorandum of Understanding completed with Chinese government officials in the Yuhang district of Hangzhou, China’s biotech hub, to develop and commercialize innovative cancer therapies starting with...
Celsion Receives $2.0 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
17 déc. 2019 08h00 HE
|
Celsion CORP
Non-Dilutive Funding Strengthens Balance Sheet; Proceeds Equate to More Than $0.08 Per Share Assures Funding Through Major Company Events; Company Provides Guidance on the Timing of Upcoming...
Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update
14 nov. 2019 16h05 HE
|
Celsion CORP
Independent Data Monitoring Committee (iDMC) Unanimously Recommends Continuation of Phase III OPTIMA Study at First Pre-Planned Efficacy AnalysisIndependent Data Safety Monitoring Board (DSMB)...
Celsion Announces Publication of Research on Fluorescence Imaging of ThermoDox® Uptake in International Journal of Hyperthermia
14 nov. 2019 08h00 HE
|
Celsion CORP
Independent Analysis Confirms Increasing Heating Time + ThermoDox® Improves Tumor Uptake of Drug, which may be visualized by real-time fluorescence imaging Study Confirms that ThermoDox® Can Deliver...
Celsion Corporation to Hold Third Quarter 2019 Financial Results Conference Call on Friday, November 15, 2019
08 nov. 2019 08h30 HE
|
Celsion CORP
Company to Provide Clinical Development Update on its Phase III OPTIMA Study in Primary Liver Cancer and its Phase I/II OVATION 2 Study in Ovarian Cancer LAWRENCEVILLE, N.J., Nov. 08, 2019 (GLOBE...
Celsion Announces DSMB Recommendation to Continue GEN-1 at 100mg/m² Dose to Complete the Phase I Portion of OVATION 2 Study in Ovarian Cancer
05 nov. 2019 08h00 HE
|
Celsion CORP
GEN-1 Manufacturing Technology Transfer Successfully Produces High-Quality Affordable Investigational Product for Use in Clinical Trials LAWRENCEVILLE, N.J., Nov. 05, 2019 (GLOBE NEWSWIRE) --...